AbbVie Inc. beat out Johnson & Johnson with a last-minute bid that clinched the $21 billion acquisition of Pharmacyclics Inc., gaining control of a blockbuster blood cancer therapy.

Deals for cancer treatments have been heating up. For more, see Cancer Drugs Spark Deal Possibilities. 

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.